Cabozantinib: a new first-line option for papillary renal cell carcinoma?

Lancet. 2021 Feb 20;397(10275):645-647. doi: 10.1016/S0140-6736(21)00316-0. Epub 2021 Feb 13.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Anilides / therapeutic use
  • Carcinoma, Renal Cell* / drug therapy
  • Humans
  • Kidney Neoplasms* / drug therapy
  • Pyridines / therapeutic use

Substances

  • Anilides
  • Pyridines
  • cabozantinib